Get the Stockscreener App
4.60
1.50%
-0.07
4 D Molecular Therapeutics Inc stock is traded at $4.60, with a volume of 62,488.
It is down -1.50% in the last 24 hours and down -1.50% over the past month.
4D Molecular Therapeutics Inc is a clinical-stage gene therapy company engaged in the development of product candidates using targeted and evolved AAV vectors. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-125, 4D-110, and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector) 4D-310.
See More
Previous Close:
$4.67
Open:
$4.74
24h Volume:
62,488
Relative Volume:
0.07
Market Cap:
$215.88M
Revenue:
$20.72M
Net Income/Loss:
$-100.84M
P/E Ratio:
-1.7293
EPS:
-2.66
Net Cash Flow:
$-78.56M
1W Performance:
-5.74%
1M Performance:
-1.50%
6M Performance:
-69.72%
1Y Performance:
-82.63%
1-Day Range:
$4.60
$4.78
1-Week Range:
$4.60
$5.07
52-Week Range:
$4.405
$36.25
4 D Molecular Therapeutics Inc Stock (FDMT) Company Profile
Name
4 D Molecular Therapeutics Inc
Sector
Industry
Phone
(510) 505-2680
Address
5858 HORTON STREET #455, EMERYVILLE
Compare FDMT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
FDMT
4 D Molecular Therapeutics Inc
|
4.60 | 215.88M | 20.72M | -100.84M | -78.56M | -2.66 |
|
VRTX
Vertex Pharmaceuticals Inc
|
480.59 | 123.34B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
696.46 | 76.09B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
647.50 | 39.34B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
251.88 | 32.49B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
116.94 | 28.26B | 3.30B | -501.07M | 1.03B | -2.1146 |
4 D Molecular Therapeutics Inc Stock (FDMT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-13-25 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Nov-21-24 | Initiated | Morgan Stanley | Underweight |
| Sep-23-24 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Apr-15-24 | Initiated | Barclays | Overweight |
| Feb-07-24 | Resumed | Goldman | Buy |
| Oct-26-23 | Initiated | RBC Capital Mkts | Outperform |
| Oct-24-23 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-18-23 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Jul-05-23 | Initiated | Chardan Capital Markets | Buy |
| Jan-30-23 | Initiated | BMO Capital Markets | Outperform |
| Nov-18-22 | Initiated | H.C. Wainwright | Buy |
| Nov-15-22 | Upgrade | Goldman | Neutral → Buy |
| Aug-12-22 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Jun-22-22 | Initiated | Jefferies | Buy |
| Jan-04-22 | Initiated | SVB Leerink | Outperform |
| Jan-05-21 | Initiated | BofA Securities | Buy |
| Jan-05-21 | Initiated | Evercore ISI | Outperform |
| Jan-05-21 | Initiated | Goldman | Neutral |
View All
4 D Molecular Therapeutics Inc Stock (FDMT) Latest News
4D Molecular Therapeutics’ (FDMT) Sell (D-) Rating Reiterated at Weiss Ratings - Defense World
4DMT to Participate in Upcoming Investor Conferences - GlobeNewswire
4D Molecular's March Investor Showcase: What These Two Major Conference Appearances Signal - StockTitan
4D Molecular Therapeutics: A Smart Bet On Long-Term VEGF Suppression - Seeking Alpha
4D Molecular Therapeutics' SWOT analysis: gene therapy firm's stock faces durability test - Investing.com
4D Molecular Therapeutics (NASDAQ:FDMT) Given New $30.00 Price Target at Chardan Capital - MarketBeat
Peapod Lane Capital LLC Purchases New Shares in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) - MarketBeat
Jefferies cuts 4D Molecular Therapeutics target to $40 - MSN
FDMT INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into 4D Molecular Therapeutics, Inc. and Encourages Stockholders to Contact the Firm! - ACCESS Newswire
FDMT INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into 4D Molecular Therapeutics, Inc. and Encourages Investors to Contact the Firm! - ACCESS Newswire
FDMT stock touches 52-week low at $4.42 amid sharp annual decline - Investing.com India
4D Molecular Therapeutics (NASDAQ:FDMT) Price Target Lowered to $30.00 at Chardan Capital - Defense World
4D Molecular Therapeutics (NASDAQ:FDMT) Given "Buy" Rating at HC Wainwright - MarketBeat
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of 4D Molecular Therapeutics, Inc.FDMT - PR Newswire
Gene Therapy In CNS Disorder Treatment Market Size Report 2032 | - openPR
Chardan Lowers Price Target on 4D Molecular Therapeutics to $30 From $39, Keeps Buy Rating - Marketscreener.com
4D Molecular Therapeutics’ (FDMT) Buy Rating Reaffirmed at HC Wainwright - Defense World
BMO Capital Markets Downgrades 4D Molecular Therapeutics Inc (FDMT) to a Market perform from an Outperform - Knox Daily
Jefferies cuts 4D Molecular Therapeutics target to $40 By Investing.com - Investing.com South Africa
4D’s new data in wet AMD bolster its phase III study vision - BioWorld Online
H.C. Wainwright maintains buy on 4D Molecular Therapeutics stock - MSN
4D Molecular Therapeutics (NASDAQ:FDMT) Earns “Buy” Rating from HC Wainwright - Armenian Reporter
Eye Disease Focused 4D Molecular Therapeutics Lays Out 52-Week Results From Wet AMD Study - Benzinga
Healthy Upside Potential: 4D Molecular Therapeutics Inc (FDMT) - SETE News
H.C. Wainwright maintains buy on 4D Molecular Therapeutics stock By Investing.com - Investing.com South Africa
Barrick Gold Corp (GOLD) receives a Neutral rating from BofA Securities - Knox Daily
A Glimpse Into The Expert Outlook On 4D Molecular Therapeutics Through 9 Analysts - Benzinga
ForexTV | Small Business Resources - ForexTV.com
4D Molecular Therapeutics Reports Positive Interim Data From Phase 2b Trial For Wet AMD - Nasdaq
4DMT Presents Positive 52-Week Results from Phase 2b Cohort - GlobeNewswire
4DMT Presents Positive 52-Week Results from Phase 2b Cohort of PRISM Wet AMD Study and Long-term Durability Data Supporting 4D-150 4FRONT Global Registration Program - GlobeNewswire Inc.
4D Molecular Therapeutics Reports Positive 52-Week Results for 4D-150 in Phase 2b PRISM Trial for Wet AMD - Nasdaq
There Is A Lot Of Upside Potential For 4D Molecular Therapeutics Inc(NASDAQ: FDMT) - Stocks Register
How Alibaba Stock Could Defy Trade Tariffs and Surge Higher - The Globe and Mail
Weiss Ratings Reiterates Sell (D-) Rating for 4D Molecular Therapeutics (NASDAQ:FDMT) - MarketBeat
A better buy-in window may exist right now for 4D Molecular Therapeutics Inc (FDMT) - SETE News
Scrip Asks... What Does 2025 Hold For Biopharma? Part 5: Clinical Trials Trends - Citeline News & Insights
Market Insights: 4D Molecular Therapeutics Inc (FDMT)’s Notable Drop of -0.17, Closing at 5.92 - The Dwinnex
4D Molecular Therapeutics Inc (FDMT) deserves deeper analysis - US Post News
4D Molecular Therapeutics Inc [FDMT] Chief Legal Officer makes an insider sale of 500 shares worth $8165.0. - Knox Daily
X-Linked Retinitis Pigmentosa Clinical Trials 2025: EMA, PDMA, - openPR
BJ’s Wholesale Club Holdings Inc (BJ) may enjoy gains as insiders got busy in the recent days - Knox Daily
Monitoring Allstate Corp (ALL) after recent insider movements - Knox Daily
The Potential Rise in the Price of Cardlytics Inc (CDLX) following insiders activity - Knox Daily
The Attractiveness of Investing In Bloomin Brands Inc (BLMN) is Growing - Knox Daily
Charting the Course: 4D Molecular Therapeutics Inc’s FDMT Stock Prospects - The InvestChronicle
Weiss Ratings Reaffirms Sell (D-) Rating for 4D Molecular Therapeutics (NASDAQ:FDMT) - Defense World
4DMT Announces Corporate Webcast to Review Interim 52-week - GlobeNewswire
4DMT Announces Corporate Webcast to Review Interim 52-week Results from the Phase 2b Cohort of PRISM in a Broad Wet AMD Population - Marketscreener.com
Breakthrough Eye Treatment Data: 4D Molecular's AMD Trial Results Coming February - StockTitan
Analysts Set 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) PT at $38.56 - Defense World
4 D Molecular Therapeutics Inc Stock (FDMT) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.42%
0.04%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):